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87  dogs  were  negative  for microfilaria  prior  to 



























































present  after  3-monthly  treatments.  Successful 
prophylactic use of moxidectin against Dirofilaria 
repens  infection  in dogs has been demonstrated 










an  infection with Dirofilaria repens  by  treating 








to  the  Investigational Veterinary Product  (IVP) 
group (T01a) using the approved dosage instruc-
























































































The  person  doing  the  modified  Knott  test  was 
blinded to treatment.
All  dogs  enrolled  in  the  study  were  monthly 








EDTA  blood  samples  were  observed  using  the 


















of  Comparative  Tropical  Veterinary  Medicine, 
LMU Munich, Germany. 










Animals enrolled and general health
One  hundred  and  eight  different  animals were 
enrolled  in  the study. Thirty-four animals were 
allocated to the treatment arm (18 in T01a, 16 in 
T03). Seventy-four dogs  (33  in T01b, 41  in T02) 











Status of infection  
































































Efficacy in the treatment of Dirofilaria repens
Efficacy in the treatment arm was evaluated based 
on  the  reduction  of microfilaria  counts  of Diro-
filaria repens comparing treatment groups T01a 


































































































































































clearance  of microfilaria  in  blood  in  all  dogs  and 
















To prove  the preventive  efficacy  of  a product  is 
often difficult. Bowman et al. (1992) reported that 




Tab. 4 Therapeutic efficacy based on prevalence of microfilaria of Dirofilaria repens from day 28 until day 112
Variable Statistic T01a (T1) T03 (T2)
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